For aiding in management/ treatment of Covid-19Ipca Laboratories announced that due to the shortage implications and/or medical necessity of certain drugs and finished products, the United States Food and Drug Administration (FDA) vide its e-mails dated 20 March, 2020 has made exception to the import alert for the Company's following Active Pharmaceutical Ingredients (APls) and finished products (Formulations) :
a. Hydroxychloroquine Sulphate and Chloroquine Phosphate APIs produced at the Company's APls manufacturing unit situated at Ratlam (Madhya Pradesh); and
b. Hydroxychloroquine Sulphate Tablets produced at the Company's formulations manufacturing units situated at SEZ Indore, Pithampur (Madhya Pradesh) and Piparia (Silvassa).
US FDA has also informed that their exception will be re-considered if the shortage implications change.
The company further announced that foreseeing the increased demand, it is gearing to manufacture and supply these products.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)